Item 7.01. Regulation FD Disclosure.

On November 9, 2012, Celgene International Sŕrl, a subsidiary of Celgene Corporation, issued a press release relating to updates on clinical studies involving AbraxaneŽ. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, that is furnished pursuant to this Item 7.01 shall not be deemed to be "filed" for the purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibit 99.1 Press Release dated November 9, 2012.

This exhibit is furnished pursuant to Item 7.01 and shall not be deemed to be "filed."

---